# National Institute of Allergy and Infectious Diseases' Biotech Investments: 28 Startups in Its Portfolio (2026) > The 28 Biotech startups National Institute of Allergy and Infectious Diseases has backed, by stage: $407M raised between them. Source: https://millionrounds.com/portfolio-maps/national-institute-of-allergy-and-infectious-diseases-biotech-portfolio (Millionrounds; every figure on the page links to its filing or article) ## Stage not reported 22 - [Antibacterial Resistance Leadership Group (ARLG)](https://millionrounds.com/company/antibacterial-resistance-leadership-group-arlg) - [ReAlta Life Sciences](https://millionrounds.com/company/realta-life-sciences) - [Institute for Bioscience and Biotechnology Research](https://millionrounds.com/company/institute-for-bioscience-and-biotechnology-research) - [Etubics](https://millionrounds.com/company/etubics) - [Blacksmith Medicines](https://millionrounds.com/company/blacksmith-medicines) - [Aldatu Biosciences](https://millionrounds.com/company/aldatu-biosciences) - [Exavir Therapeutics](https://millionrounds.com/company/exavir-therapeutics) - [Omniose](https://millionrounds.com/company/omniose) - [Scanogen](https://millionrounds.com/company/scanogen) - [Trethera](https://millionrounds.com/company/trethera) - [Moonlight Therapeutics](https://millionrounds.com/company/moonlight-therapeutics) - [Resvita Bio](https://millionrounds.com/company/resvita-bio) - [Sapience Therapeutics](https://millionrounds.com/company/sapience-therapeutics) - [Enrich Therapeutics](https://millionrounds.com/company/enrich-therapeutics) - [Phase Genomics](https://millionrounds.com/company/phase-genomics) - [Arisan Therapeutics](https://millionrounds.com/company/arisan-therapeutics) - [Iaso Therapeutics](https://millionrounds.com/company/iaso-therapeutics) - [Kephera Diagnostics](https://millionrounds.com/company/kephera-diagnostics) - [Sunflower Therapeutics](https://millionrounds.com/company/sunflower-therapeutics) - [Kovina Therapeutics](https://millionrounds.com/company/kovina-therapeutics) - [Truly Technologies](https://millionrounds.com/company/truly-technologies) - [Versatope Therapeutics](https://millionrounds.com/company/versatope-therapeutics) ## Series A 2 - [Forge Therapeutics](https://millionrounds.com/company/forge-therapeutics) - [TFF Pharmaceuticals](https://millionrounds.com/company/tff-pharmaceuticals) ## Series C and later 2 - [ILiAD Biotechnologies](https://millionrounds.com/company/iliad-biotechnologies) - [Siolta Therapeutics](https://millionrounds.com/company/siolta-therapeutics) ## Series B 2 - [Osivax](https://millionrounds.com/company/osivax) - [InDevR](https://millionrounds.com/company/indevr) ## Segment by segment ### Stage not reported 22 startups · $184M raised - [**Antibacterial Resistance Leadership Group (ARLG)**](https://millionrounds.com/company/antibacterial-resistance-leadership-group-arlg) Antibacterial Resistance Leadership Group (ARLG) is a research network for which the Duke Clinical Research Institute United States $103M - [**ReAlta Life Sciences**](https://millionrounds.com/company/realta-life-sciences) ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases. United States $40M - [**Institute for Bioscience and Biotechnology Research**](https://millionrounds.com/company/institute-for-bioscience-and-biotechnology-research) IBBR is leverages state-of-art integrative methods for bioanalytical, biophysical and structural characterization of biomolecules. United States $6.9M - [**Etubics**](https://millionrounds.com/company/etubics) Etubics Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington, founded in 2003. United States $4.4M - [**Blacksmith Medicines**](https://millionrounds.com/company/blacksmith-medicines) Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. United States $3.3M - [**Aldatu Biosciences**](https://millionrounds.com/company/aldatu-biosciences) Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases. United States $3.0M - [**Exavir Therapeutics**](https://millionrounds.com/company/exavir-therapeutics) Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections. United States $3.0M - [**Omniose**](https://millionrounds.com/company/omniose) Omniose is an early stage biotechnological company. United States $3.0M ### Series A 2 startups · $40M raised - [**Forge Therapeutics**](https://millionrounds.com/company/forge-therapeutics) Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry. United States $21M - [**TFF Pharmaceuticals**](https://millionrounds.com/company/tff-pharmaceuticals) TFF Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drug products. United States $19M ### Series C and later 2 startups · $128M raised - [**ILiAD Biotechnologies**](https://millionrounds.com/company/iliad-biotechnologies) ILiAD Biotechnologies, LLC is a clinical-stage biotechnology company based in Weston, Florida, focused on the prevention and treat United States $116M - [**Siolta Therapeutics**](https://millionrounds.com/company/siolta-therapeutics) Siolta Therapeutics, Inc. United States $12M ### Series B 2 startups · $55M raised - [**Osivax**](https://millionrounds.com/company/osivax) Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies. France $39M - [**InDevR**](https://millionrounds.com/company/indevr) InDevR develops and manufactures microarray technologies as well as novel solutions to support the life science industry. United States $16M **How this map is made.** Every startup here works in Biotech and has raised money in a round we track that names National Institute of Allergy and Infectious Diseases as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026. ## More portfolio maps [All portfolios](https://millionrounds.com/portfolio-maps) [Sector portfolio **National Cancer Institute (NCI)'s Biotech portfolio** 34 startups · $361M](https://millionrounds.com/portfolio-maps/national-cancer-institute-nci-biotech-portfolio)[Sector portfolio **Mayo Clinic's Healthtech portfolio** 22 startups · $2.1B](https://millionrounds.com/portfolio-maps/mayo-clinic-healthtech-portfolio)[Sector portfolio **Mayo Clinic's Biotech portfolio** 19 startups · $479M](https://millionrounds.com/portfolio-maps/mayo-clinic-biotech-portfolio)[Sector portfolio **AVP's AI portfolio** 17 startups · $1.1B](https://millionrounds.com/portfolio-maps/avp-2-ai-portfolio)[Sector portfolio **Square 1 Bank's Biotech portfolio** 14 startups · $1.6B](https://millionrounds.com/portfolio-maps/square-1-bank-biotech-portfolio)[Sector portfolio **Mayo Clinic's AI portfolio** 13 startups · $256M](https://millionrounds.com/portfolio-maps/mayo-clinic-ai-portfolio) ## Raising from investors like National Institute of Allergy and Infectious Diseases? Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports. [Find investors](https://millionrounds.com/login?join=1&next=/app/investors)[Market maps](https://millionrounds.com/market-maps)